At the ISPOR Warsaw 2019 regional conference, a panel examined country experiences with managed entry agreements and their impact on improving access to innovative oncology therapies.
This article summarizes the lessons learned from implementing managed entry and multi-year, multi-indication agreements in different regional contexts.
Drug price controls in the US: A roundtable discussion with experts
The United States is the world leader in innovative drug development, supporting patients and health systems globally by advancing the creation of new cures...